Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For previously untreated patients with Lg-B-NHL or MCL~Inclusion Criteria~Patients who satisfy all of the conditions listed below:~▪ Patients who satisfy all of the following criteria A) to D): A) Patients who are histopathologically confirmed to have one of the following subtypes of CD20 (cluster of differentiation 20)-positive Lg-B-NHL or MCL (excluding transformed lymphoma) by lymph node biopsy or evaluable tissue biopsy (World Health Organization \[WHO\] histological classification \[4th edition\]).~* Small lymphocytic lymphoma~* Splenic marginal zone lymphoma~* Lymphoplasmacytic lymphoma~* Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)~* Nodal marginal zone lymphoma~* Follicular lymphoma (Grade 1, 2, 3a)~* MCL B) Patients who have at least one measurable lesion (\>1.5 cm in major axis on computed tomography \[CT\]).~C) Patients without a history of treatment for lymphoma. D) Patients with at least one of the following clinical signs or symptoms (with the exception of MCL patients).~1. Bulky disease \>7 cm in major axis on CT (excluding lesions in the spleen)~2. B symptoms~   * Unexplained fever exceeding 38.0ºC~  * Night sweats~  * Weight loss of more than 10% within 6 months before registration~3. Elevated serum lactate dehydrogenase (LDH) or β2-microglobulin level~4. Involvement of at least 3 regional lymph nodes \>3 cm in major axis on CT~5. Symptomatic splenomegaly~6. Compressive symptoms~7. Pleural effusion and/or ascites~   * Patients aged between 20 and 79 years (at the time of registration).~  * Patients who are expected to survive for at least 3 months.~  * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.~  * Patients with adequate functional reserve of major organs (bone marrow, heart, lungs, liver, kidneys, etc.).~     * Neutrophil count: ≥1,500/mm\^3~    * Platelet count: ≥75,000/mm\^3~    * Aspartate aminotransferase (AST) \[glutamic oxaloacetic transaminase \[GOT\]): ≤3.0 times the institution's upper limit of normal (ULN)~    * Alanine aminotransferase (ALT) \[glutamic pyruvic transaminase (GPT)\]: ≤3.0 times the institution's ULN~    * Total bilirubin: \<2.0 mg/dL~    * Serum creatinine: \<2.0 mg/dL~    * Percutaneous arterial oxygen saturation (SpO2): ≥95% or Partial arterial oxygen pressure (PaO2): ≥65 mmHg~    * No abnormal findings requiring treatment on electrocardiogram (ECG)~    * Left ventricular ejection fraction (LVEF) on echocardiography: ≥55%~  * Patients who have provided written informed consent to participate in this study.~Exclusion Criteria~Patients who meet any of the following conditions will be excluded:~* MCL patients aged ≤65 years (at the time of registration).~* Patients who have a history of treatment for Lg-B-NHL or MCL (chemotherapy, radiotherapy, antibody therapy or antitumor steroid therapy).~* Patients who have previously received hematopoietic stem cell transplantation.~* Patients with invasion to central nervous system (CNS) or clinical symptoms suspected of CNS invasion.~* Patients with serious active infection (requiring antibiotic, antifungal, or antiviral IV injection).~* Patients with serious complications (such as hepatic failure and renal failure).~* Patients with concurrent or previous, serious cardiac disease (e.g., myocardial infarction, ischemic heart disease); however, patients with arrhythmias are allowed to be enrolled if it does not require treatment at the time of registration.~* Patients with serious gastrointestinal symptoms (such as high-grade or severe nausea/vomiting or diarrhea).~* Patients with malignant pleural effusion, pericardial effusion, or ascites.~* Patients positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody (patients with positive hepatitis B virus \[HBV\]-DNA quantitative test results if they are negative for HBs antigen and positive for HBs antibody or hepatitis B core \[HBc\] antibody).~* Patients with serious bleeding tendencies (such as disseminated intravascular coagulation \[DIC\]).~* Patients with a fever of 38.0ºC or higher (with the exception of fever developing as a B symptom).~* Patients with concurrent or previous interstitial pneumonia, pulmonary fibrosis, or chronic obstructive pulmonary disease.~* Patients with active multiple primary cancers or patients with a history of other malignancy within the past 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or digestive organs.~* Patients with concurrent or previous autoimmune hemolytic anemia.~* Patients who have previously received bendamustine hydrochloride.~* Patients who have received a cytokine preparation, such as granulocyte colony- stimulating factor (G-CSF) or erythropoietin, or blood transfusions within 2 weeks before a screening test for this study.~* Patients who have received other investigational products or unapproved drugs within 3 months before registration for this study.~* Patients with a history of allergy to medications similar to SyB L-0501RI (e.g., alkylating agents and purine-nucleoside derivatives).~* Patients who cannot tolerate rituximab.~* Pregnant, possibly pregnant, or lactating women.~* Patients, whether male or female, who do not agree to use contraception.~Duration:~Male patients; during the treatment period and for 6 months after treatment Female patients with no menstruation; during the treatment period Female patients with menstruation; during the treatment period and for 3 months after treatment~* Patients with drug addiction, narcotic addiction, or alcohol dependence.~* Patients who are unable to take pre-treatment medication due to drug allergies or the like.~* Patients who are otherwise judged by the investigator or subinvestigator to be unsuitable as a subject.~For patients with recurrent or refractory DLBCL~Inclusion Criteria~Patients who satisfy all of the conditions listed below:~▪ Patients who satisfy both of the following criteria A and B: A) Patients who are histopathologically confirmed to have CD20-positive DLBCL (excluding transformed lymphoma) by lymph node biopsy or evaluable tissue biopsy (WHO histological classification \[4th edition\]).~B) Patients with recurrent or refractory DLBCL who have had disease progression after standard rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy or R-CHOP-like therapy as first-line treatment.~* Patients aged between 20 and 79 years (at the time of registration).~* Patients who are expected to survive for at least 3 months.~* Patients with an ECOG PS of 0 to 2.~* Patients with adequate functional reserve of major organs (bone marrow, heart, lungs, liver, kidneys, etc.).~  * Neutrophil count: ≥1,500/mm\^3~ * Platelet count: ≥75,000/mm\^3~ * AST (GOT): ≤3.0 times the institution's ULN~ * ALT (GPT): ≤3.0 times the institution's ULN~ * Total bilirubin: \<2.0 mg/dL~ * Serum creatinine: \<2.0 mg/dL~ * SpO2: ≥95% or PaO2: ≥65 mmHg~ * No abnormal findings requiring treatment on ECG~ * LVEF on echocardiography: ≥55%~* Patients who have provided written informed consent to participate in this study.~Exclusion Criteria~Patients who meet any of the following conditions will be excluded:~* Patients with an off-treatment interval of less than 3 weeks between the last day of preceding treatment (chemotherapy, radiotherapy, antibody therapy, or antitumor steroid therapy) for DLBCL and the day of registration for this study.~* Patients who are judged by the investigator or subinvestigator to be suitable for autologous peripheral blood stem cell transplantation.~* Patients who have previously received allogeneic hematopoietic stem cell transplantation.~* Patients who have previously received radioimmunotherapy~* Patients with invasion to CNS or clinical symptoms suspected of CNS invasion.~* Patients with serious active infection (requiring antibiotic, antifungal, or antiviral IV injection).~* Patients with serious complications (such as hepatic failure and renal failure).~* Patients with concurrent or previous, serious cardiac disease (e.g., myocardial infarction, ischemic heart disease); however, patients with arrhythmias are allowed to be enrolled if it does not require treatment at the time of registration.~* Patients with serious gastrointestinal symptoms (such as high-grade or severe nausea/vomiting or diarrhea).~* Patients with malignant pleural effusion, pericardial effusion, or ascites.~* Patients positive for HBs antigen, HCV antibody, or HIV antibody (patients with positive HBV-DNA quantitative test results if they are negative for HBs antigen and positive for HBs antibody or HBc antibody).~* Patients with serious bleeding tendencies (such as DIC).~* Patients with a fever of 38.0ºC or higher (with the exception of fever developing as a B symptom).~* Patients with concurrent or previous interstitial pneumonia, pulmonary fibrosis, or chronic obstructive pulmonary disease.~* Patients with active multiple primary cancers or patients with a history of other malignancy within the past 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or digestive organs.~* Patients with concurrent or previous autoimmune hemolytic anemia.~* Patients who have previously received bendamustine hydrochloride.~* Patients who have received a cytokine preparation, such as G-CSF or erythropoietin, or blood transfusions within 2 weeks before a screening test for this study.~* Patients who have received other investigational products or unapproved drugs within 3 months before registration for this study.~* Patients with a history of allergy to medications similar to SyB L-0501RI (e.g., alkylating agents and purine-nucleoside derivatives).~* Patients who cannot tolerate rituximab.~* Pregnant, possibly pregnant, or lactating women.~* Patients, whether male or female, who do not agree to use contraception.~Duration:~Male patients; during the treatment period and for 6 months after treatment Female patients with no menstruation; during the treatment period Female patients with menstruation; during the treatment period and for 3 months after treatment~* Patients with drug addiction, narcotic addiction, or alcohol dependence.~* Patients who are unable to take pre-treatment medication due to drug allergies or the like.~* Patients who are otherwise judged by the investigator or subinvestigator to be unsuitable as a subject.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Lg-B-NHL or MCL (Type: EXPERIMENTAL): For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m\^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
- DLBCL (Type: EXPERIMENTAL): For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m\^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).